Ocugen (OCGN) Price & Analysis

Compare

6,073 Followers

OCGN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.52 - $1.33

Previous CloseN/A

Volume1.89M

Average Volume (3M)2.62M

Market Cap

$324.80M

Enterprise Value$289.23M

Total Cash (Recent Filing)$27.01M

Total Debt (Recent Filing)$32.82M

Price to Earnings (P/E)―

Beta1.37

Next Earnings

Nov 07, 2025

EPS Estimate

-0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding312,304,750

10 Day Avg. Volume1,867,733

30 Day Avg. Volume2,620,544

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.89

Enterprise Value/Revenue60.84

Enterprise Value/Gross Profit60.84

Enterprise Value/Ebitda-5.53

Forecast

1Y Price Target

$5.00

Price Target Upside380.77% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Pipeline DevelopmentsThe Phase 3 pivotal study liMeliGhT for retinitis pigmentosa is ongoing without any reported serious adverse events, indicating a positive safety profile.

Strategic TransactionsOcugen has entered into agreements for multiple potentially value-creating transactions such as the Orthocellix spinout and the Definitive Agreement for OCU400 partnering in Korea.

Bears Say

Financial PerformanceOcugen reported 2Q25 results with a net loss of ($14.7M) and a cash position of $27.0M.

Operational RisksThere is limited insight into the terms of funds raise, complete design of pivotal study, and the management team that would be responsible for the development of NeoCart.

Ocugen News

Ocugen reports EMA positive advice for acceptability of OCU410ST

Ocugen (OCGN) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines...

16d ago

OCGN

Ocugen announces $20M registered direct offering of common stock, warrants

Ocugen (OCGN) announced that it has entered into a securities purchase agreement with Janus Henderson Investors to purchase...

20d ago

OCGN

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Cardiff Oncology (CRDF) 38.29%...

28d ago

LAC

LQD

Ocugen reports Q2 EPS (5c), consensus (6c)

Reports Q2 revenue $1.37M, consensus $350,000. “While our modifier gene therapy clinical trials advance-now with two in late-stage-we...

28d ago

OCGN

Ocugen sees cash runway into 1Q26

The Company’s cash, cash equivalents, and restricted cash totaled $27.3 million as of June 30, 2025, compared to...

28d ago

OCGN

Ocugen signs term sheet for exclusive Korean rights to OCU400

Aligned with Ocugen’s (OCGN) business development strategy to pursue regional partnerships for OCU400, the Company signed a binding...

28d ago

OCGN

Options Volatility and Implied Earnings Moves Today, August 01, 2025

Today, several major companies are expected to report earnings: Bristol-Myers Squibb (BMY), Chevron (CVX), Dominion Energy (D), Enbridge...

28d ago

ABR

Ocugen’s Strategic Advancements and Financial Positioning Underpin Buy Rating

Ocugen, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Okunewitch from Maxim...

15d ago

OCGN

Ocugen Announces $20M Securities Purchase Agreement

An update from Ocugen ( ($OCGN) ) is now available. On August 8, 2025, Ocugen, Inc. announced a...

18d ago

OCGN

Ocugen’s Growth Potential Highlighted by Pivotal Studies and Strong Financial Position

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Ocugen, with a...

24d ago

OCGN

Ocugen Reports Progress in Gene Therapy Trials

Ocugen Inc ( ($OCGN) ) has released its Q2 earnings. Here is a breakdown of the information Ocugen...

27d ago

OCGN

Ocugen Inc’s Earnings Call: Progress Amid Financial Challenges

Ocugen Inc (($OCGN)) has held its Q2 earnings call. Read on for the main highlights of the call....

27d ago

OCGN

Ocugen Wins Dismissal of Securities Lawsuit

An update from Ocugen ( ($OCGN) ) is now available. On July 29, 2025, the U.S. District Court...

29d ago

OCGN

Is OCGN a Buy, Before Earnings?

Ocugen Inc (OCGN) is scheduled to report 2nd quarter earnings on 08/01/2025, before the market opens. Regarding Q2...

30d ago

OCGN

OCGN FAQ

What was Ocugen Inc’s price range in the past 12 months?

Ocugen Inc lowest stock price was $0.52 and its highest was $1.33 in the past 12 months.

What is Ocugen Inc’s market cap?

Ocugen Inc’s market cap is $324.80M.

When is Ocugen Inc’s upcoming earnings report date?

Ocugen Inc’s upcoming earnings report date is Nov 07, 2025 which is in 70 days.

How were Ocugen Inc’s earnings last quarter?

Ocugen Inc released its earnings results on Aug 01, 2025. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.056 by $0.006.

Is Ocugen Inc overvalued?

According to Wall Street analysts Ocugen Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ocugen Inc pay dividends?

Ocugen Inc does not currently pay dividends.

What is Ocugen Inc’s EPS estimate?

Ocugen Inc’s EPS estimate is -0.06.

How many shares outstanding does Ocugen Inc have?

Ocugen Inc has 312,304,750 shares outstanding.

What happened to Ocugen Inc’s price movement after its last earnings report?

Ocugen Inc reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.056. Following the earnings report the stock price went down -3.883%.

Which hedge fund is a major shareholder of Ocugen Inc?

Currently, no hedge funds are holding shares in OCGN

Ocugen Stock Smart Score

Neutral

Fundamentals

Return on Equity

-569.99%

Trailing 12-Months

Asset Growth

32.19%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ocugen Inc

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative gene therapies to treat eye diseases. The company operates primarily in the biotechnology sector, with a core focus on developing therapies for retinal diseases and other ocular conditions. Ocugen's lead product candidate, OCU300, is designed to treat ocular diseases, leveraging its proprietary modifier gene therapy platform.

Ocugen (OCGN) Earnings & Revenues

Historic Earnings Reports

OCGN Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant progress in clinical development and strategic partnerships, including FDA and EMA approvals, and successful clinical trial data. However, there are concerns about declining cash reserves and operating expenses.View all OCGN earnings summaries

OCGN Stock 12 Month Forecast

Average Price Target

$5.00

▲(380.77% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.99,1.5292307692307692,2.0684615384615386,2.6076923076923073,3.146923076923077,3.6861538461538457,4.225384615384615,4.764615384615384,5.303846153846154,5.843076923076923,6.382307692307692,6.921538461538461,7.46076923076923,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.99,1.2984615384615386,1.606923076923077,1.9153846153846152,2.2238461538461536,2.5323076923076924,2.8407692307692307,3.149230769230769,3.457692307692308,3.7661538461538457,4.0746153846153845,4.383076923076923,4.691538461538461,{"y":5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.99,0.9907692307692307,0.9915384615384615,0.9923076923076923,0.9930769230769231,0.9938461538461538,0.9946153846153846,0.9953846153846154,0.9961538461538462,0.9969230769230769,0.9976923076923077,0.9984615384615385,0.9992307692307693,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.39,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.73,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.65,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.84,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >